Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency.
|
9177423 |
1997 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
After 40 weeks of 40 mg atorvastatin treatment decreases in total cholesterol, triglycerides, and apolipoprotein B of 40%, 43%, and 41%, respectively, were observed in the combined dyslipidaemia group, and of 46%, 40%, and 43% in the dysbetalipoproteinaemic patients.
|
12181212 |
2002 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
LHGDN |
ApoB100-LDL acts as a metabolic signal from liver to peripheral fat causing inhibition of lipolysis in adipocytes.
|
19020660 |
2008 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Association of polymorphisms at restriction enzyme recognition sites of apolipoprotein B and E gene with dyslipidemia in children undergoing primary nephrotic syndrome.
|
18512131 |
2009 |
Dyslipidemias
|
0.400 |
Therapeutic
|
group |
CTD_human |
Atherogenic dyslipidemia is associated with increased levels of chylomicrons and their remnants containing 3 main components: apolipoprotein B-48, triglycerides and cholesterol ester of intestinal origin.
|
18230960 |
2008 |
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Common familial lipid disorders associated with premature heart disease include familial lipoprotein(a) excess, familial dyslipidemia (elevated triglycerides and decreased HDL cholesterol), familial combined hyperlipidemia (elevations of LDL cholesterol and triglycerides, and often decreased HDL cholesterol), familial hypoapobetalipoproteinemia (elevated apolipoprotein B levels), familial hypoalphalipoproteinemia (low HDL cholesterol levels), and familial hypercholesterolemia (elevated LDL cholesterol levels).
|
7802728 |
1994 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Common variants in OGFOD3 and APOB as well as rare and common BAD variants were significantly (p<0.05) associated with dyslipidemia.
|
29126409 |
2017 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Hammerhead ribozyme as a therapeutic agent for hyperlipidemia: production of truncated apolipoprotein B and hypolipidemic effects in a dyslipidemia murine model.
|
11096445 |
2000 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, the performance of LDL-C using this new method (LDL-N) is compared with LDL-C estimated with Friedewald equation (LDL-F) in familial combined hyperlipidemia (FCHL), a common primary dyslipidemia in which apolipoprotein B containing particle composition is abnormal and interferes with LDL-C estimation.
|
29970255 |
2018 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In individuals with mixed dyslipidemia rare synonymous variants within LPL gene were associated with attenuated response to FA therapy while APOCIII rare variants were associated with a modest effect on APOB response to FA-statin therapy.
|
24704626 |
2014 |
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In the present study, the case of an 18‑year‑old male who presented with MS characteristics with central obesity (overweight and a waist circumference of 95 cm) and dyslipidemia (high TG, low HDL levels and low apoA‑I/apoB‑100) was reported.
|
23921547 |
2013 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
In this article we reviewed some of the current therapeutic targets for the treatment of dyslipidemia, with a primary focus on endothelial lipase and lecithin cholesterol acyl transferase for raising HDL-C, and the proprotein convertase subtilisin-like kexin type 9 (PCSK9), microsomal triglyceride transfer protein, and the messenger RNA of apolipoprotein B for lowering LDL-C.
|
24334831 |
2014 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we focus on dyslipidemia drug targets traceable to human genetic studies, including statins and ezetimibe, as well as promising new classes such as inhibitors of proprotein convertase subtilisin kexin 9, apolipoprotein B, microsomal triglyceride transfer protein, cholesteryl ester transfer protein, angiopoietin-like proteins types 3 and 4 and apolipoprotein C-III.
|
28109622 |
2017 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
IR and associated dyslipidaemia are the major determinants of low-density apoB-associated LVP in fasting plasma.
|
20940286 |
2011 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Of the remaining 38 children, 23 had non-hereditary abnormalities of low (LDL) or high density lipoprotein (HDL) cholesterol or apolipoprotein B. Fifteen children were suspected to have genetically determined dyslipidemias or a combination of risk factors: in four, possible familial hypercholesterolaemia (FH); in five, possible familial combined hyperlipidaemia; in three, hereditary low HDL cholesterol; and in three a combination of high LDL cholesterol and Lp(a) lipoprotein concentrations.
|
10735834 |
2000 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Purpose of this review is to discuss the available data on the effects of various ASO used for the treatment of dyslipidemia, with the main focus on ASO against ApoB-100, the most advanced in clinical development, and on PCSK9.
|
21418033 |
2011 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Relationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia.
|
26345861 |
2015 |
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease.
|
17462654 |
2008 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Selected dyslipidemia guidelines recommend non-high-density lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (apoB) as secondary targets to the primary target of low-density lipoprotein-cholesterol (LDL-C).
|
29506984 |
2018 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Several studies have identified APOB as a candidate gene predisposing individuals to dyslipidemia.
|
25292352 |
2014 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial.
|
29381796 |
2018 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The apolipoprotein B (APOB) gene has been reported to be a candidate gene for individual susceptibility to dyslipidemia and obesity.
|
25837208 |
2015 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The association between angiotensin-converting enzyme (ACE) as well as apolipoprotein B polymorphisms and dyslipidemia and coronary artery disease (CAD) is controversial.
|
10781757 |
2000 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The current study reinforces the current knowledge that carrying APOB rs693 is an independent risk factor for dyslipidemia and higher LDL levels.
|
23247049 |
2013 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The link between hepatic insulin signaling and apolipoprotein B (apoB) production has important implications in understanding the etiology of metabolic dyslipidemia commonly observed in insulin-resistant states.
|
17288985 |
2007 |